NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.19 -0.81 (-5.79 %) (As of 04/6/2020 06:48 AM ET) Add Compare Share Today's Range$12.76Now: $13.19▼$14.7350-Day Range$11.52MA: $17.81▼$24.1852-Week Range$10.63Now: $13.19▼$28.81Volume403,688 shsAverage Volume102,165 shsMarket Capitalization$324.08 millionP/E RatioN/ADividend YieldN/ABeta1.36 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Crinetics Pharmaceuticals has a potential upside of 172.9% from its current price of $13.19.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCrinetics Pharmaceuticals has received 78 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCrinetics Pharmaceuticals has received 91 “underperform” votes. (Add your “underperform” vote.)Community SentimentCrinetics Pharmaceuticals has received 53.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,034,975.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions85.10% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to grow by 10.43% in the coming year, from ($2.78) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRNX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.crinetics.com/ Phone858-450-6464Debt Debt-to-Equity Ratio0.04 Current Ratio14.79 Quick Ratio14.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.19 million Price / Sales272.33 Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book2.73Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-50,420,000.00 Net MarginsN/A Return on Equity-37.27% Return on Assets-33.91%Miscellaneous Employees47 Outstanding Shares24,570,000Market Cap$324.08 million Next Earnings Date5/11/2020 (Estimated) OptionableNot Optionable Receive CRNX News and Ratings via Email Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CRNX Rates by TradingView Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions How has Crinetics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRNX shares have decreased by 14.9% and is now trading at $13.19. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Crinetics Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crinetics Pharmaceuticals. When is Crinetics Pharmaceuticals' next earnings date? Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Crinetics Pharmaceuticals. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced its quarterly earnings data on Monday, March, 9th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.68) by $0.08. The company earned $0.32 million during the quarter, compared to analyst estimates of $0.30 million. View Crinetics Pharmaceuticals' earnings history. What price target have analysts set for CRNX? 3 analysts have issued 1 year price targets for Crinetics Pharmaceuticals' stock. Their forecasts range from $35.00 to $37.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $36.00 in the next year. This suggests a possible upside of 172.9% from the stock's current price. View analysts' price targets for Crinetics Pharmaceuticals. What are Wall Street analysts saying about Crinetics Pharmaceuticals stock? Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock: 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (3/16/2020) 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019) Has Crinetics Pharmaceuticals been receiving favorable news coverage? Media coverage about CRNX stock has trended very negative on Monday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutCrinetics Pharmaceuticals. Who are some of Crinetics Pharmaceuticals' key competitors? Some companies that are related to Crinetics Pharmaceuticals include Pacira Biosciences (PCRX), Constellation Pharmaceuticals (CNST), Ligand Pharmaceuticals (LGND), Innoviva (INVA), Karyopharm Therapeutics (KPTI), ZEALAND PHARMA/S (ZEAL), Tricida (TCDA), Heron Therapeutics (HRTX), Zogenix (ZGNX), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), I-Mab (ARQT) and NextCure (NXTC). What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX) and Applied Genetic Technologies (AGTC). Who are Crinetics Pharmaceuticals' key executives? Crinetics Pharmaceuticals' management team includes the following people: Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)Dr. Alan S. Krasner, Chief Medical Officer (Age 56)Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53) When did Crinetics Pharmaceuticals IPO? (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. What is Crinetics Pharmaceuticals' stock symbol? Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX." How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Crinetics Pharmaceuticals' stock price today? One share of CRNX stock can currently be purchased for approximately $13.19. How big of a company is Crinetics Pharmaceuticals? Crinetics Pharmaceuticals has a market capitalization of $324.08 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe. View additional information about Crinetics Pharmaceuticals. What is Crinetics Pharmaceuticals' official website? The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/. How can I contact Crinetics Pharmaceuticals? Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: How much can an individual set aside as a catch-up contribution?
